Latest Healthcare News

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Ansell Limited delivered a robust FY25 performance driven by organic growth, successful Kimberly-Clark PPE integration, and productivity gains, while advancing sustainability goals and managing trade headwinds.

Medibank has set ambitious goals to triple its health segment earnings by FY30, expand its private health insurance market share, and double its health engagement, signaling a strategic pivot towards integrated, technology-driven care.

Hydrix Limited reports a robust quarter with $3.35 million in sales, a 7% revenue increase, and a strong international client base, while advancing US market ventures.

OncoSil Medical Limited has addressed ASX concerns over delayed disclosure of PANCOSIL clinical trial results, confirming compliance with continuous disclosure obligations despite procedural oversights.

Anteris Technologies Global Corp. has had its trading suspension lifted following a key announcement about its capital raising plans, signaling renewed market activity.

Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

dorsaVi reports breakthrough RRAM sensor performance and secures a major US physical therapy deal, backed by a $5 million capital raise and new leadership appointments.